Clinical Trial Update: mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian [Phase 1]

View source ↗

Summary

A Phase 1 study investigating AZD2014 (an mTORC1/2 inhibitor) or AZD5363 (an AKT inhibitor) in recurrent endometrial and ovarian cancers, with inclusion of BRCA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Triple-negative Breast Cancer
• Uterine Corpus Cancer

Drugs mentioned

• AZD2014 (vistusertib)
• AZD5363 (capivasertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Status: ACTIVE_NOT_RECRUITING